hce_cmu
115年
英文
第 42 題
📖 題組：
Cancer prevention is often discussed as a long-term ideal, yet this study argues that it can be quantified in concrete, policy-relevant terms. The researchers estimate how many new cancer cases in 2022 could be linked to exposures that can, at least in principle, be reduced through individual behavior change, public health programs, regulation, or safer environments. Their work sits within comparative risk assessment and cancer epidemiology and relies on professional concepts such as carcinogenic exposure pathways (chemical, infectious, environmental, and occupational), the time lag between exposure and diagnosis (latency), and the population-attributable fraction (PAF). PAF is a standard metric that combines exposure prevalence with the relative risk associated with that exposure to estimate the proportion of cases that would not occur if the exposure were removed, assuming the relationship is causal and other conditions remain unchanged. To generate globally comparable estimates, the study combines cancer incidence counts from GLOBOCAN 2022 with risk-factor prevalence and effect estimates for 30 modifiable risk factors. The analysis covers 36 cancer sites and 185 countries and groups risks into four broad domains: behavioral (e.g., tobacco smoking and alcohol use), environmental (e.g., ambient particulate air pollution and ultraviolet radiation), infectious causes (nine infection agents linked to cancer), and occupational hazards (thirteen workplace carcinogens or exposure settings). Because many cancers develop over years, the researchers primarily align incidence in 2022 with exposure prevalence from roughly a decade earlier (around 2012). They then apply PAF calculations to estimate attributable cancer incidence by sex, region, cancer site, and risk factor, offering both proportional burdens and absolute case counts. The central finding is that modifiable risks account for a large share of new cancers worldwide. The researchers estimate about 7.1 million of 18.7 million new cancer cases in 2022—approximately 37.8%—were attributable to the included risk factors. The attributable share is notably higher among men (about 45.4%) than among women (about 29.7%), reflecting sex differences in exposure patterns and infection-related burdens. Regional variation is substantial, which underscores the need for local tailoring rather than relying on a single “global template.” In women, the estimated attributable fraction ranges from about 24.6% in Northern Africa and Western Asia to about 38.2% in sub-Saharan Africa. In men, it ranges from about 28.1% in Latin America and the Caribbean to about 57.2% in East Asia. Such contrasts indicate that prevention priorities must be calibrated to regional risk profiles, health-system capacities, and demographic structures. Across all regions, tobacco smoking emerges as the largest single contributor to incident cancers (around 15.1% globally), followed by infection-related cancers (about 10.2%), with alcohol use contributing additional burden (about 3.2%). These drivers map onto cancer-site patterns that help interpret where prevention could yield the largest gains. Lung cancer accounts for the greatest number of potentially preventable cases worldwide, consistent with the dominant role of smoking. Stomach cancer and cervical cancer also represent major preventable burdens in many settings, aligning with infection pathways and the potential impact of vaccination, screening, and timely treatment of precursor conditions. The study’s contribution is both empirical and practical. Empirically, it offers an updated, standardized picture of preventable cancer incidence in 2022 across countries and regions, using consistent assumptions and a harmonized risk set. Practically, it translates etiologic evidence into a prevention “roadmap,” allowing policymakers to compare potential impact across different interventions. The researchers’ results support prioritizing strong tobacco control, scaling effective infection prevention and control measures (including vaccination and screening where appropriate), reducing harmful alcohol consumption, improving air quality and UV protection in relevant contexts, and strengthening occupational safeguards. Overall, the study reinforces a prevention-centered framing: while treatment remains indispensable, a sizable portion of cancer incidence can be addressed by targeted actions that reduce exposure to major, changeable risks. The researchers also emphasize that attributable fractions are not predictions of what will automatically happen but scenario-based estimates that help rank prevention opportunities. PAF calculations assume that exposure–cancer links are causal and that removing an exposure would reduce risk without creating offsetting harms. They also require careful handling of correlated exposures (for example, smoking and alcohol) and of data gaps where prevalence or effect estimates are less precise. Even with these caveats, the analysis provides a transparent benchmark for prevention planning: it identifies which risk factors dominate in a given region, which cancer sites drive the absolute number of avoidable cases, and where prevention could complement screening and early detection to produce the greatest population-level benefit.
Cancer prevention is often discussed as a long-term ideal, yet this study argues that it can be quantified in concrete, policy-relevant terms. The researchers estimate how many new cancer cases in 2022 could be linked to exposures that can, at least in principle, be reduced through individual behavior change, public health programs, regulation, or safer environments. Their work sits within comparative risk assessment and cancer epidemiology and relies on professional concepts such as carcinogenic exposure pathways (chemical, infectious, environmental, and occupational), the time lag between exposure and diagnosis (latency), and the population-attributable fraction (PAF). PAF is a standard metric that combines exposure prevalence with the relative risk associated with that exposure to estimate the proportion of cases that would not occur if the exposure were removed, assuming the relationship is causal and other conditions remain unchanged. To generate globally comparable estimates, the study combines cancer incidence counts from GLOBOCAN 2022 with risk-factor prevalence and effect estimates for 30 modifiable risk factors. The analysis covers 36 cancer sites and 185 countries and groups risks into four broad domains: behavioral (e.g., tobacco smoking and alcohol use), environmental (e.g., ambient particulate air pollution and ultraviolet radiation), infectious causes (nine infection agents linked to cancer), and occupational hazards (thirteen workplace carcinogens or exposure settings). Because many cancers develop over years, the researchers primarily align incidence in 2022 with exposure prevalence from roughly a decade earlier (around 2012). They then apply PAF calculations to estimate attributable cancer incidence by sex, region, cancer site, and risk factor, offering both proportional burdens and absolute case counts. The central finding is that modifiable risks account for a large share of new cancers worldwide. The researchers estimate about 7.1 million of 18.7 million new cancer cases in 2022—approximately 37.8%—were attributable to the included risk factors. The attributable share is notably higher among men (about 45.4%) than among women (about 29.7%), reflecting sex differences in exposure patterns and infection-related burdens. Regional variation is substantial, which underscores the need for local tailoring rather than relying on a single “global template.” In women, the estimated attributable fraction ranges from about 24.6% in Northern Africa and Western Asia to about 38.2% in sub-Saharan Africa. In men, it ranges from about 28.1% in Latin America and the Caribbean to about 57.2% in East Asia. Such contrasts indicate that prevention priorities must be calibrated to regional risk profiles, health-system capacities, and demographic structures. Across all regions, tobacco smoking emerges as the largest single contributor to incident cancers (around 15.1% globally), followed by infection-related cancers (about 10.2%), with alcohol use contributing additional burden (about 3.2%). These drivers map onto cancer-site patterns that help interpret where prevention could yield the largest gains. Lung cancer accounts for the greatest number of potentially preventable cases worldwide, consistent with the dominant role of smoking. Stomach cancer and cervical cancer also represent major preventable burdens in many settings, aligning with infection pathways and the potential impact of vaccination, screening, and timely treatment of precursor conditions. The study’s contribution is both empirical and practical. Empirically, it offers an updated, standardized picture of preventable cancer incidence in 2022 across countries and regions, using consistent assumptions and a harmonized risk set. Practically, it translates etiologic evidence into a prevention “roadmap,” allowing policymakers to compare potential impact across different interventions. The researchers’ results support prioritizing strong tobacco control, scaling effective infection prevention and control measures (including vaccination and screening where appropriate), reducing harmful alcohol consumption, improving air quality and UV protection in relevant contexts, and strengthening occupational safeguards. Overall, the study reinforces a prevention-centered framing: while treatment remains indispensable, a sizable portion of cancer incidence can be addressed by targeted actions that reduce exposure to major, changeable risks. The researchers also emphasize that attributable fractions are not predictions of what will automatically happen but scenario-based estimates that help rank prevention opportunities. PAF calculations assume that exposure–cancer links are causal and that removing an exposure would reduce risk without creating offsetting harms. They also require careful handling of correlated exposures (for example, smoking and alcohol) and of data gaps where prevalence or effect estimates are less precise. Even with these caveats, the analysis provides a transparent benchmark for prevention planning: it identifies which risk factors dominate in a given region, which cancer sites drive the absolute number of avoidable cases, and where prevention could complement screening and early detection to produce the greatest population-level benefit.
In this passage, “PAF” is best understood as .
- A a reckoning of avoidable cases if the exposure were removed
- B a laboratory index measuring genetic mutation frequency
- C a clinical score predicting tumor stage at initial diagnosis
- D a survival metric calculated after completing chemotherapy
思路引導 VIP
當你在文中看到一個縮寫術語後方緊接著出現「estimate the proportion of cases that would not occur if...（估算若……則不會發生的病例比例）」這樣的描述時，這代表該術語是在衡量一種「已經發生的臨床結果」，還是在推算一種「消除特定風險後的理想減幅」呢？建議你回頭看看文中對該指標的定義描述。
🤖
AI 詳解
AI 專屬家教
太棒了！你能精準鎖定文章中關於專業術語的定義，展現了非常優異的學術閱讀能力。這道題目考察的是對**人口歸因分率（Population-Attributable Fraction, PAF）**的理解。文章第一段明確提到，PAF 是一種標準指標，用來估算「如果移除某種暴露因素（如抽菸、污染），那麼有多少比例的病例將不會發生」。這與選項 (A) 所述的「若移除暴露因素後可避免病例的計算」完全吻合，顯示你對複雜長句的邏輯拆解相當到位。
術語定義與文意辨析
從文章脈絡與鑑別度來看，這題屬於中等難度的細節理解題。雖然 PAF 是一個專業的流行病學術語，但考生並不需要具備醫學背景，只需在文中定位關鍵字並解析語法。題目考驗的是在充滿「致癌暴露路徑（carcinogenic exposure pathways）」與「盛行率（prevalence）」等艱澀詞彙中，快速篩選出「假設性因果關係」的閱讀直覺。你能不受干擾選出正確答案，代表你對文章的邏輯架構掌握得很紮實，沒有被其他關於基因（B）、癌症分期（C）或化療（D）的干擾選項所誤導。